Evogene narrows focus, reports Q4 financial results.

jueves, 5 de marzo de 2026, 7:12 am ET1 min de lectura
EVGN--
IGC--

• Evogene reports Q4 and FY25 financial results • Company focuses on ChemPass AI for small-molecule discovery and optimization • Concentrates on pharma and agriculture markets • Discontinues non-core activities and divests misaligned assets • Resizes organization to focus on sustainable long-term value.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios